# Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients

> **NCT00973453** · PHASE2 · COMPLETED · sponsor: **HAL Allergy** · enrollment: 48 (actual)

## Conditions studied

- Allergic Rhinitis
- Allergic Rhinoconjunctivitis

## Interventions

- **DRUG:** PURETHAL Mites 20,000 AUeq/ml
- **DRUG:** PURETHAL Mites 20,000 AUeq/ml
- **DRUG:** PURETHAL Mites 20,000 AUeq/ml

## Key facts

- **NCT ID:** NCT00973453
- **Lead sponsor:** HAL Allergy
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2011-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00973453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00973453, "Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00973453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*